Cargando…
Acute glycemic control in diabetics. How sweet is oprimal? Con: Just as sweet as in nondiabetic is better
This review is for Con side of “Pro-Con debate” on the optimal target of blood glucose levels in patients with chronic hyperglycemia (e.g. premorbid HbA1c level > 7%). Currently, international guideline recommended that blood glucose level ≤ 180 mg/dL in critically ill patients irrespective of pr...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219026/ https://www.ncbi.nlm.nih.gov/pubmed/30410766 http://dx.doi.org/10.1186/s40560-018-0337-1 |
_version_ | 1783368568358830080 |
---|---|
author | Egi, Moritoki |
author_facet | Egi, Moritoki |
author_sort | Egi, Moritoki |
collection | PubMed |
description | This review is for Con side of “Pro-Con debate” on the optimal target of blood glucose levels in patients with chronic hyperglycemia (e.g. premorbid HbA1c level > 7%). Currently, international guideline recommended that blood glucose level ≤ 180 mg/dL in critically ill patients irrespective of presence or absence of premorbid diabetes. However, there are several studies to generate the hypothesis that liberal glycemic control (e.g., target blood glucose level 180–250 mg/dL) may be beneficial in critically ill patients with premorbid hyperglycemia. Although there is before-after study to report its safety and feasibility, it should be noted that this strategy may have a potential to increase the risk of infection, glycosuria, and polyneuropathy. Furthermore, there is randomized controlled study which showed the potential harm of liberal glycemic control in patients with premorbid hyperglycemia. Additionally, there are lots of uncertainty about the candidate and methodology of such a permissive hyperglycemia. With considering these facts, it might be better to keep target of blood glucose level in patients with diabetes the same as patients without diabetes (≤ 180 mg/dL), until randomized control study as like LUCID (the Liberal GlUcose Control in Critically Ill Patients with Pre-existing Type 2 Diabetes) trial will justify its risk and benefit. |
format | Online Article Text |
id | pubmed-6219026 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-62190262018-11-08 Acute glycemic control in diabetics. How sweet is oprimal? Con: Just as sweet as in nondiabetic is better Egi, Moritoki J Intensive Care Review This review is for Con side of “Pro-Con debate” on the optimal target of blood glucose levels in patients with chronic hyperglycemia (e.g. premorbid HbA1c level > 7%). Currently, international guideline recommended that blood glucose level ≤ 180 mg/dL in critically ill patients irrespective of presence or absence of premorbid diabetes. However, there are several studies to generate the hypothesis that liberal glycemic control (e.g., target blood glucose level 180–250 mg/dL) may be beneficial in critically ill patients with premorbid hyperglycemia. Although there is before-after study to report its safety and feasibility, it should be noted that this strategy may have a potential to increase the risk of infection, glycosuria, and polyneuropathy. Furthermore, there is randomized controlled study which showed the potential harm of liberal glycemic control in patients with premorbid hyperglycemia. Additionally, there are lots of uncertainty about the candidate and methodology of such a permissive hyperglycemia. With considering these facts, it might be better to keep target of blood glucose level in patients with diabetes the same as patients without diabetes (≤ 180 mg/dL), until randomized control study as like LUCID (the Liberal GlUcose Control in Critically Ill Patients with Pre-existing Type 2 Diabetes) trial will justify its risk and benefit. BioMed Central 2018-11-06 /pmc/articles/PMC6219026/ /pubmed/30410766 http://dx.doi.org/10.1186/s40560-018-0337-1 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Egi, Moritoki Acute glycemic control in diabetics. How sweet is oprimal? Con: Just as sweet as in nondiabetic is better |
title | Acute glycemic control in diabetics. How sweet is oprimal? Con: Just as sweet as in nondiabetic is better |
title_full | Acute glycemic control in diabetics. How sweet is oprimal? Con: Just as sweet as in nondiabetic is better |
title_fullStr | Acute glycemic control in diabetics. How sweet is oprimal? Con: Just as sweet as in nondiabetic is better |
title_full_unstemmed | Acute glycemic control in diabetics. How sweet is oprimal? Con: Just as sweet as in nondiabetic is better |
title_short | Acute glycemic control in diabetics. How sweet is oprimal? Con: Just as sweet as in nondiabetic is better |
title_sort | acute glycemic control in diabetics. how sweet is oprimal? con: just as sweet as in nondiabetic is better |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219026/ https://www.ncbi.nlm.nih.gov/pubmed/30410766 http://dx.doi.org/10.1186/s40560-018-0337-1 |
work_keys_str_mv | AT egimoritoki acuteglycemiccontrolindiabeticshowsweetisoprimalconjustassweetasinnondiabeticisbetter |